Top

Published in:

01-06-2015 | Commentary

Oxaliplatin-induced neuropathy: a tale of two electrolytes

Authors: Hani M. Babiker, Myke R. Green, Mark A. Nelson, Emad Elquza

Published in: Supportive Care in Cancer | Issue 6/2015

Excerpt

Colorectal cancer ranks as the fourth most prevalent cancer in the USA based on the Surveillance, Epidemiology, and End Results (SEER) cancer statistics. The incidence and deaths in 2014 of colorectal cancer is estimated to be 136,830 and 50,310, respectively [1]. The 5-year survival for all stages combined is 64.7 % based on recent SEER data. Incidence rates for colorectal cancer have been falling on average 3.1 % per year over the last 10 years. Death rates have been decreasing on average 2.9 % per year from 2002 to 2011 [1]. …

Surveillance, Epidemiology, and End Results Program. National Cancer Institute. SEER Stat Fact Sheets: Colon and Rectum Cancer, SEER 18 2004-2010. http://seer.cancer.gov/statfacts/html/colorect.html. Accessed Dec 29, 2014

Raymond E, Faivre S, Woynarowski JM et al (1998) Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25(2 Suppl 5):4–12PubMed

Raymond E, Buquet-Fagot C, Djelloul S et al (1997) Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anti-Cancer Drugs 8(9):876–85CrossRefPubMed

de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938–47PubMed

Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–51CrossRefPubMed

Grothey A, Hart LL, Rowland KM et al (2008) Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial. J Clin Oncol (Meeting Abstracts) 26(15):4010

Saif MW, Readron J (2005) Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 1(4):249–58PubMedCentralPubMed

Taieb S, Trillet-Lenoir V, Rambaud L et al (2002) Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 94(9):2434–40CrossRefPubMed

Adelsberger H, Quasthoff S, Grosskreutz J et al (2000) The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 406(1):25–32CrossRefPubMed

10.

Gamelin L, Boisdron-Celle M, Delva R et al (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10(12 Pt 1):4055–61CrossRefPubMed

11.

Grothey A, Nikcevich DA, Sloan JA et al (2011) Intravenous calcium and magnesium for oxaliplatin-induced neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 29(4):421–7CrossRefPubMedCentralPubMed

12.

Loprinzi CL, Qin R, Dakhil SR et al Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol (10):997-1005

13.

Atkins CD (2014) Estimating the value of intravenous calcium and magnesium in ameliorating oxaliplatin-induced neuropathy. J Clin Oncol 32(29):3341CrossRefPubMed

14.

Avan A, Avan A, Giovannetti E et al (2014) Calcium/magnesium infusion for oxaliplatin-induced neuropathy: protective or not? J Clin Oncol 32(29):3341CrossRefPubMed

15.

Nativi C, Gualdani R, Dragoni E et al (2005) A TRPA1 antagonist reverts oxaliplatin-induced neuropathic pain. Sci Rep 3:2005. doi:10.1038/srep02005

16.

Aziz MT, Good BL, Lowe DK et al (2014) Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy. Ann Pharmacother 48(5):626–32, 2014CrossRefPubMed

17.

Ibrahim MM, Deng H, Zvonok A et al (2003) Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A 100(18):10529–33CrossRefPubMedCentralPubMed

Title: Oxaliplatin-induced neuropathy: a tale of two electrolytes
Authors: Hani M. Babiker
Myke R. Green
Mark A. Nelson
Emad Elquza
Publication date: 01-06-2015
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 6/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-015-2702-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2015

Minimally invasive palliative procedures in oncology: a review of a multidisciplinary collaboration

NRS-2002 for pre-treatment nutritional risk screening and nutritional status assessment in head and neck cancer patients

Moxibustion for the treatment of chemotherapy-induced leukopenia: a systematic review of randomized clinical trials

The interaction between informal cancer caregivers and health care professionals: a survey of caregivers’ experiences of problems and unmet needs

Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency

Complementary and alternative medicine for cancer patients: results of the EPAAC survey on integrative oncology centres in Europe

Keynote webinar | Spotlight on antibody–drug conjugates in cancer